Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling. In Vitro Angstrom6 is effective at blocking the migration of the OVCAR8, OVCAR3, ES2, IGROV-1, MDA-MB-468, and MDA-MB361 cells with IC 50 s in the range of 10 to 100 nM. ?\nAngstrom6 potentiates the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Angstrom6 (100 mg/kg; s.c. twice daily) reduces the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57Bl/6 mice (bearing B16-F10 cells)Dosage: 100 mg/kg Administration: S.c.; twice a day for 11 days Result: Reduced the number of lung nodules and reduced the number of lung metastases to 50% of control. Form:Solid